A Phase I Clinical Trial of Ad 5 / 3-Δ 24 , a Novel Serotype-Chimeric , Infectivity-Enhanced , Conditionally-Replicative Adenovirus ( CRAd ) , in Patients with Recurrent Ovarian Cancer